Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles

PHASE4CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

August 1, 2021

Study Completion Date

October 1, 2021

Conditions
SterilityInfertility
Interventions
DRUG

Progesterone

Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.

Trial Locations (1)

Unknown

American University of Beirut Medical Center, Beirut

All Listed Sponsors
lead

American University of Beirut Medical Center

OTHER

NCT03619707 - Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles | Biotech Hunter | Biotech Hunter